Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases

Second-line treatment for metastatic or locally advanced urothelial cancer (UC) is limited. Immunotherapy is approved as a second-line treatment for metastatic UC. Its use as a first-line agent is limited to patients who are ineligible for cisplatin-based treatments. The fibroblast growth factor rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Teng, Hu, Wuyun, Jin, Lan, Yin, Xianghua, Kang, Dongxu, Piao, Longzhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141313/
https://www.ncbi.nlm.nih.gov/pubmed/37124509
http://dx.doi.org/10.3389/fonc.2023.1164368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141313/
https://www.ncbi.nlm.nih.gov/pubmed/37124509
http://dx.doi.org/10.3389/fonc.2023.1164368

Ejemplares similares